Display options
Cite
Dyomina AV, Zubareva OE, Smolensky IV, et al. Anakinra Reduces Epileptogenesis, Provides Neuroprotection, and Attenuates Behavioral Impairments in Rats in the Lithium-Pilocarpine Model of Epilepsy. Pharmaceuticals (Basel). 2020;13(11)doi: 10.3390/ph13110340.
Dyomina, A. V., Zubareva, O. E., Smolensky, I. V., Vasilev, D. S., Zakharova, M. V., Kovalenko, A. A., Schwarz, A. P., Ischenko, A. M., & Zaitsev, A. V. (2020). Anakinra Reduces Epileptogenesis, Provides Neuroprotection, and Attenuates Behavioral Impairments in Rats in the Lithium-Pilocarpine Model of Epilepsy. Pharmaceuticals (Basel, Switzerland), 13(11), . https://doi.org/10.3390/ph13110340
Dyomina, Alexandra V, et al. "Anakinra Reduces Epileptogenesis, Provides Neuroprotection, and Attenuates Behavioral Impairments in Rats in the Lithium-Pilocarpine Model of Epilepsy." Pharmaceuticals (Basel, Switzerland) vol. 13,11 (2020). doi: https://doi.org/10.3390/ph13110340
Dyomina AV, Zubareva OE, Smolensky IV, Vasilev DS, Zakharova MV, Kovalenko AA, Schwarz AP, Ischenko AM, Zaitsev AV. Anakinra Reduces Epileptogenesis, Provides Neuroprotection, and Attenuates Behavioral Impairments in Rats in the Lithium-Pilocarpine Model of Epilepsy. Pharmaceuticals (Basel). 2020 Oct 25;13(11). doi: 10.3390/ph13110340. PMID: 33113868; PMCID: PMC7692198.
Copy Download .nbib Format: NLM
Share it on

Pharmaceuticals (Basel). 2020 Oct 25;13(11). doi: 10.3390/ph13110340.

Anakinra Reduces Epileptogenesis, Provides Neuroprotection, and Attenuates Behavioral Impairments in Rats in the Lithium-Pilocarpine Model of Epilepsy.

Pharmaceuticals (Basel, Switzerland)

Alexandra V Dyomina, Olga E Zubareva, Ilya V Smolensky, Dmitry S Vasilev, Maria V Zakharova, Anna A Kovalenko, Alexander P Schwarz, Alexander M Ischenko, Aleksey V Zaitsev

Affiliations

  1. Sechenov Institute of Evolutionary Physiology and Biochemistry of RAS, 44, Toreza Prospekt, 194223 Saint Petersburg, Russia.
  2. Research Institute of Highly Pure Biopreparations, Federal Medical-Biological Agency, 7, Pudozhskaya Street, 197110 Saint Petersburg, Russia.

PMID: 33113868 PMCID: PMC7692198 DOI: 10.3390/ph13110340

Abstract

Temporal lobe epilepsy is a widespread chronic disorder that manifests as spontaneous seizures and is often characterized by refractoriness to drug treatment. Temporal lobe epilepsy can be caused by a primary brain injury; therefore, the prevention of epileptogenesis after a primary event is considered one of the best treatment options. However, a preventive treatment for epilepsy still does not exist. Neuroinflammation is directly involved in epileptogenesis and neurodegeneration, leading to the epileptic condition and cognitive decline. In the present study, we aimed to clarify the effect of treatment with a recombinant form of the Interleukin-1 receptor antagonist (anakinra) on epileptogenesis and behavioral impairments in rats using the lithium-pilocarpine model. We found that anakinra administration during the latent phase of the model significantly suppressed the duration and frequency of spontaneous recurrent seizures in the chronic phase. Moreover, anakinra administration prevented some behavioral impairments, including motor hyperactivity and disturbances in social interactions, during both the latent and chronic periods. Histological analysis revealed that anakinra administration decreased neuronal loss in the CA1 and CA3 areas of the hippocampus but did not prevent astro- and microgliosis. The treatment increased the expression level of the solute carrier family 1 member 2 gene (

Keywords: Gfap; Il1b; Itpr2; Slc1a2; Tnfa; anakinra; behavior; epileptogenesis; gliosis; hippocampus; lithium–pilocarpine model; mRNA; spontaneous recurrent seizures; temporal lobe epilepsy

References

  1. Brain Res. 2005 Feb 9;1034(1-2):172-9 - PubMed
  2. Neuroscience. 2016 Jul 7;327:146-55 - PubMed
  3. Mol Cell Probes. 2020 Oct;53:101611 - PubMed
  4. Neurobiol Dis. 2013 Nov;59:183-93 - PubMed
  5. Int Rev Psychiatry. 2017 Oct;29(5):409-424 - PubMed
  6. Pain. 2008 Apr;135(3):232-9 - PubMed
  7. Br J Pharmacol. 2011 Feb;162(3):659-72 - PubMed
  8. Electroencephalogr Clin Neurophysiol. 1975 Jan;38(1):1-12 - PubMed
  9. J Neurosci. 2011 Jan 19;31(3):1081-92 - PubMed
  10. Curr Med Chem. 2014;21(6):663-88 - PubMed
  11. J Cell Physiol. 2011 Oct;226(10):2484-93 - PubMed
  12. J Intern Med. 2011 Oct;270(4):319-26 - PubMed
  13. Cardiovasc Drugs Ther. 2009 Apr;23(2):129-35 - PubMed
  14. Cancer Res. 2004 Aug 1;64(15):5245-50 - PubMed
  15. Clin Exp Immunol. 2004 Jul;137(1):65-73 - PubMed
  16. Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 - PubMed
  17. Pharm Res. 2013 Nov;30(11):2951-66 - PubMed
  18. Biomol Detect Quantif. 2015 Mar 11;3:9-16 - PubMed
  19. Sci Signal. 2010 Jan 19;3(105):cm1 - PubMed
  20. Synapse. 2008 Apr;62(4):302-9 - PubMed
  21. Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11534-9 - PubMed
  22. Neurotherapeutics. 2011 Apr;8(2):304-15 - PubMed
  23. Nat Rev Neurol. 2011 Jan;7(1):31-40 - PubMed
  24. Neurol Sci. 2018 Nov;39(11):1945-1953 - PubMed
  25. Neuropharmacology. 2020 May 15;168:107762 - PubMed
  26. Neurobiol Dis. 2009 Feb;33(2):171-81 - PubMed
  27. Psychol Bull. 1976 May;83(3):482-504 - PubMed
  28. J Neurosci. 2017 Aug 16;37(33):7864-7877 - PubMed
  29. Front Mol Neurosci. 2018 Jun 26;11:215 - PubMed
  30. J Neuroinflammation. 2015 Feb 25;12:38 - PubMed
  31. Neuropsychopharmacology. 2004 Feb;29(2):327-34 - PubMed
  32. Epilepsy Res. 2009 Jul;85(1):31-45 - PubMed
  33. CNS Drugs. 2020 Nov;34(11):1089-1103 - PubMed
  34. Neuropharmacology. 2015 Sep;96(Pt A):70-82 - PubMed
  35. J Neuroinflammation. 2018 Feb 09;15(1):38 - PubMed
  36. Neurobiol Dis. 2010 Feb;37(2):461-7 - PubMed
  37. Int J Neurosci. 2016;126(1):70-5 - PubMed
  38. J Biol Chem. 2014 Feb 28;289(9):6188-98 - PubMed
  39. Epilepsia. 2010 Jul;51 Suppl 3:34-8 - PubMed
  40. Neurochem Int. 2013 Dec;63(7):660-9 - PubMed
  41. J Vis Exp. 2018 Feb 27;(132): - PubMed
  42. BMC Mol Biol. 2008 May 28;9:53 - PubMed
  43. Nat Neurosci. 2011 Mar;14(3):297-9 - PubMed
  44. Chem Biol Interact. 2006 Mar 25;160(2):134-49 - PubMed
  45. Neurobiol Dis. 2012 Aug;47(2):145-54 - PubMed
  46. Cardiovasc Diabetol. 2014 Dec 18;13:158 - PubMed
  47. Lancet Neurol. 2005 Mar;4(3):171-8 - PubMed
  48. Transl Psychiatry. 2015 Jun 09;5:e579 - PubMed
  49. Br J Pharmacol. 1978 Jan;62(1):19-24 - PubMed
  50. Epilepsy Behav. 2015 Dec;53:131-4 - PubMed
  51. Neuropharmacology. 2020 May 1;167:107605 - PubMed
  52. Br J Pharmacol. 2010 May;160(1):153-9 - PubMed
  53. Biotechnol Lett. 2004 Mar;26(6):509-15 - PubMed
  54. Neuroscience. 2006;137(1):301-8 - PubMed
  55. Nature. 2005 Jan 6;433(7021):73-7 - PubMed
  56. Eur J Pharmacol. 2018 Oct 15;837:145-155 - PubMed
  57. J Neurosci. 2003 Sep 24;23(25):8692-700 - PubMed
  58. Behav Brain Res. 2019 Oct 17;372:112044 - PubMed
  59. Blood. 2011 Apr 7;117(14):3720-32 - PubMed
  60. Front Pharmacol. 2018 Nov 06;9:1157 - PubMed
  61. J Neuroinflammation. 2011 Feb 11;8(1):14 - PubMed
  62. Nat Rev Neurosci. 2008 Jan;9(1):46-56 - PubMed
  63. Epilepsia. 2017 Jul;58 Suppl 3:48-56 - PubMed
  64. Methods. 2001 Dec;25(4):402-8 - PubMed
  65. Ann Neurol. 2012 Jul;72(1):82-90 - PubMed
  66. Int J Mol Sci. 2019 Nov 21;20(23): - PubMed
  67. Neuropathol Appl Neurobiol. 2018 Feb;44(1):112-129 - PubMed
  68. J Neurosci Res. 2009 Jan;87(1):34-41 - PubMed
  69. Cold Spring Harb Perspect Med. 2015 Jun 22;5(8):a022863 - PubMed
  70. J Cereb Blood Flow Metab. 2008 Feb;28(2):387-94 - PubMed
  71. Epilepsy Behav. 2014 Aug;37:59-70 - PubMed
  72. Life Sci. 2007 Aug 2;81(8):673-82 - PubMed
  73. BMC Res Notes. 2012 Dec 13;5:685 - PubMed
  74. Brain Behav Immun. 2008 Nov;22(8):1117-27 - PubMed
  75. BMC Mol Biol. 2006 Oct 06;7:33 - PubMed
  76. Psychopharmacology (Berl). 1987;93(3):358-64 - PubMed
  77. J Neuroinflammation. 2018 May 15;15(1):144 - PubMed
  78. Epilepsia. 2010 Jul;51 Suppl 3:2-17 - PubMed
  79. Nat Protoc. 2006;1(2):581-5 - PubMed
  80. Biol Pharm Bull. 2005 Jan;28(1):143-7 - PubMed
  81. J Neurophysiol. 2004 Nov;92(5):2909-19 - PubMed
  82. Ann Neurol. 2016 Dec;80(6):939-945 - PubMed

Publication Types

Grant support